FDA Picks Devices for Home Health Innovation Challenge

Selected wireless EEG monitor and infant vibrational mattress advance in the agency's READI-Home program aimed at cutting hospital readmissions.

Updated on Nov. 3, 2026 in Healthcare

FDA Picks Devices for Home Health Innovation Challenge

Live Poll

Would you trust a home medical device to monitor your health after a hospital stay?

The FDA has selected initial participants for its READI-Home Innovation Challenge, a program intended to reduce hospital readmissions by speeding home-use medical devices to patients after an acute stay. Selected devices include Epitel's REMI wireless EEG system and Prapela's vibrational crib mattress.

Why it matters

Avoidable readmissions create significant logistical and financial challenges for patients and the healthcare system. The program aims to accelerate patient access to home-use device technologies following hospital discharge.

REMI's home use applies to individuals six years and older, applied at the point of discharge. The extraction provides no selection count or readmission-rate outcome, and the program's measurable impact on readmissions has not yet been reported.

The players

U.S. Food and Drug Administration (FDA)

The federal agency that regulates medical devices in the United States and runs the READI-Home Innovation Challenge.

Epitel

A neurotechnology company whose REMI wireless EEG system was selected for home monitoring.

Current Health Limited

The developer of the CRS Solution, an AI-based software medical device selected to advance to the FDA interaction phase.

Skribe Medical

The maker of the Aurora System, a wearable multi-sensor adhesive patch selected to advance to the interaction phase.

The details

The FDA selected Epitel's REMI Neuro Monitoring Home Health Hub, a wireless wearable EEG system for extended monitoring of sleep and seizures, and Prapela's Therapeutic Vibrational Crib Mattress, which delivers low-amplitude vibration during infant sleep. Separately, BD Self-Collection Kit, CRS Solution from Current Health Limited, and the Aurora System from Skribe Medical advance to an interaction phase providing early FDA engagement and feedback on device design and testing.

- Article on the FDA's initial participant selections published November 3, 2026.

Industry Dynamics

The READI-Home challenge builds on the FDA's Breakthrough Devices Program by applying accelerated engagement to home-use devices that support recovery after hospital discharge. It signals a federal focus on shifting monitoring and care from hospitals into patients' homes.

For patients recovering after a hospital stay, home-use devices like REMI could allow continuous neurological monitoring outside a clinic. Parents of infants may eventually have access to vibrational mattresses designed for home sleep, pending FDA review.

The takeaway

Medical devices designed for home use may increasingly shape how patients are monitored after discharge. Tracking FDA program outcomes can clarify which home-based technologies reach market next.

What happens next

Selected participants will advance to an interaction phase with the FDA for early engagement, though no specific dates were provided in the source extraction.